• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体内注射阿柏西普与全视网膜光凝治疗增生型糖尿病视网膜病变的临床疗效比较:系统评价和荟萃分析方案。

Clinical efficacy of intravitreal aflibercept injection versus vitrectomy with panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis.

机构信息

Department of Ophthalmology, Wuhan Eyegood Ophthalmic, Wuhan, China.

出版信息

Medicine (Baltimore). 2021 Apr 9;100(14):e25354. doi: 10.1097/MD.0000000000025354.

DOI:10.1097/MD.0000000000025354
PMID:33832114
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8036057/
Abstract

BACKGROUND

In the current literature, it is still controversial whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) patients. Given that there is no high-quality meta-analysis or review to incorporate existing evidence, the purpose of this study is to systematically review the level I evidence in the literature to ascertain whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with PRP for PDR patients.

METHODS

The systematic literature review is structured to adhere to PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses), which include requirements deemed essential for the transparent reporting of results. A systematic search will be performed in Web of Science, Embase, Scopus, Science Direct, Cochrane Library up to and inclusive of March 19, 2021. The method of data extraction will follow the approach outlined by the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcome is change in best-corrected visual acuity. The secondary outcomes are change in area of neovascularization and change in area of retinal nonperfusion. Where disagreement occurs, this will be resolved through discussion. All outcomes are pooled on random-effect model. A P value of < .05 is considered to be statistically significant.

RESULTS

The results of our review will be reported strictly following the PRISMA criteria.

CONCLUSIONS

The hypothesis of the study was that visual acuity recovery would be faster with vitrectomy because the blood is mechanically cleared during surgery.

REGISTRATION NUMBER

10.17605/OSF.IO/NCAXW.

摘要

背景

在当前的文献中,关于对于增生型糖尿病视网膜病变(PDR)患者,玻璃体内注射阿柏西普是否能比全视网膜光凝(PRP)联合玻璃体切除术提供更好的视力恢复,仍存在争议。鉴于没有高质量的荟萃分析或综述来整合现有证据,本研究旨在系统地回顾文献中的 I 级证据,以确定玻璃体内注射阿柏西普是否能比 PRP 联合玻璃体切除术为 PDR 患者提供更好的视力恢复。

方法

系统文献综述的结构符合 PRISMA 指南(系统评价和荟萃分析的首选报告项目),包括对结果透明报告被认为是必不可少的要求。将在 Web of Science、Embase、Scopus、Science Direct、Cochrane Library 中进行系统搜索,截至并包括 2021 年 3 月 19 日。数据提取方法将遵循 Cochrane 干预系统评价手册中概述的方法。主要结局是最佳矫正视力的变化。次要结局是新生血管面积的变化和视网膜无灌注面积的变化。如果出现分歧,将通过讨论解决。所有结局都采用随机效应模型进行汇总。P 值<.05 被认为具有统计学意义。

结果

我们的综述结果将严格按照 PRISMA 标准报告。

结论

该研究的假设是,玻璃体切除术的视力恢复会更快,因为手术过程中血液会被机械清除。

注册号

10.17605/OSF.IO/NCAXW。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ce/8036057/9cc8d608efdc/medi-100-e25354-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ce/8036057/9cc8d608efdc/medi-100-e25354-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ce/8036057/9cc8d608efdc/medi-100-e25354-g001.jpg

相似文献

1
Clinical efficacy of intravitreal aflibercept injection versus vitrectomy with panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis.玻璃体内注射阿柏西普与全视网膜光凝治疗增生型糖尿病视网膜病变的临床疗效比较:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Apr 9;100(14):e25354. doi: 10.1097/MD.0000000000025354.
2
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.玻璃体积血患者增生性糖尿病视网膜病变中玻璃体内注射阿柏西普与全视网膜光凝联合玻璃体切除术对视力的影响:一项随机临床试验。
JAMA. 2020 Dec 15;324(23):2383-2395. doi: 10.1001/jama.2020.23027.
3
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.52 周时玻璃体内注射阿柏西普与全视网膜光凝治疗增生性糖尿病视网膜病变患者最佳矫正视力的临床疗效(CLARITY):一项多中心、单盲、随机、对照、2b 期、非劣效性临床试验。
Lancet. 2017 Jun 3;389(10085):2193-2203. doi: 10.1016/S0140-6736(17)31193-5. Epub 2017 May 7.
4
Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.玻璃体内注射阿柏西普联合全视网膜光凝与早期玻璃体切除术治疗糖尿病性玻璃体积血:随机临床试验。
BMC Ophthalmol. 2020 Apr 6;20(1):130. doi: 10.1186/s12886-020-01401-4.
5
Clinical efficacy and acceptability of panretinal photocoagulation combined with conbercept for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis.全视网膜光凝联合康柏西普治疗增生型糖尿病视网膜病变的临床疗效及可接受性:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Apr 30;100(17):e25611. doi: 10.1097/MD.0000000000025611.
6
Clinical efficacy of anti-vascular endothelial growth factor versus panretinal photocoagulation for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis.抗血管内皮生长因子与全视网膜光凝治疗增生型糖尿病视网膜病变的临床疗效比较:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Apr 30;100(17):e25682. doi: 10.1097/MD.0000000000025682.
7
Infographic: Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation in patients with proliferative diabetic retinopathy (PDR): the CLARITY study.信息图:阿柏西普玻璃体内注射与全视网膜光凝治疗增殖性糖尿病视网膜病变(PDR)患者的临床疗效比较:CLARITY研究
Eye (Lond). 2024 Aug;38(Suppl 2):26-27. doi: 10.1038/s41433-023-02391-5. Epub 2023 Apr 21.
8
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的随机临床试验
JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
9
Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.玻璃体内抗血管内皮生长因子、全视网膜光凝及联合治疗增殖性糖尿病视网膜病变:一项系统评价和网状Meta分析
Acta Ophthalmol. 2021 Sep;99(6):e795-e805. doi: 10.1111/aos.14681. Epub 2020 Dec 16.
10
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.抗血管内皮生长因子治疗增殖性糖尿病视网膜病变
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD008721. doi: 10.1002/14651858.CD008721.pub2.